Callisto Pharmaceuticals
420 Lexington Avenue, Suite 1609
New York
New York
10170
United States
Tel: 212-297-0010
Fax: 212-297-0020
Website: http://www.callistopharma.com/
Email: Jacob@callistopharma.com
93 articles about Callisto Pharmaceuticals
-
Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals
1/18/2013
-
Callisto Pharmaceuticals Stockholders Approve Merger With Synergy Pharmaceuticals
1/15/2013
-
Synergy Pharmaceuticals Signs Definitive Agreement to Acquire Callisto Pharmaceuticals
7/23/2012
-
Callisto Pharmaceuticals Adjourns Annual Stockholders Meeting Due to Lack of a Quorum
7/12/2010
-
Callisto Pharmaceuticals Redirects Atiprimod Clinical Development to Treat Rheumatoid Arthritis
1/27/2009
-
Callisto Pharmaceuticals’ Majority-Owned Subsidiary Synergy Pharmaceuticals Completes Phase I Trial of SP-304 in Volunteers
12/9/2008
-
Callisto Pharmaceuticals Announces $3.0 Million Financing by Its Synergy Pharmaceuticals Subsidiary and Related Transactions Leaving Callisto with a 68% Stake in Synergy
7/21/2008
-
Callisto Pharmaceuticals Opens Phase I Clinical Trial of SP-304 to Treat Chronic Constipation and Irritable Bowel Syndrome
6/4/2008
-
Callisto Pharmaceuticals Reports Promising Interim Phase II Data for Atiprimod in Advanced Carcinoid Cancer
5/16/2008
-
Callisto Pharmaceuticals Receives Notice of Delisting From AMEX - Subject to Appeal
4/14/2008
-
Callisto Pharmaceuticals Files IND for SP-304 (Guanilib) in Chronic Constipation and Irritable Bowel Syndrome
4/7/2008
-
Callisto Pharmaceuticals Announces Guanilib Presentation at the 5th Annual Meeting of Cancer Drugs Research and Development
2/19/2008
-
Callisto Pharmaceuticals to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/8/2008
-
Callisto Pharmaceuticals Announces Investor Conference Call to Provide Details on Guanilib Strategic Initiative in GI Disorders
1/8/2008
-
Callisto Pharmaceuticals Amends and Restates Atiprimod License Agreement with Genzyme Corporation
1/7/2008
-
Callisto Pharmaceuticals Announces Presentation on Guanilib at 2007 Crohn's and Colitis Foundation National Research and Clinical Conference
12/3/2007
-
Callisto Pharmaceuticals to Present at Biotechnology Industry Organization (BIO) Investor Forum 2007
10/4/2007
-
Callisto Pharmaceuticals Announces Major Strategic Initiative for Guanilib in GI Disorders
10/3/2007
-
Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
9/20/2007
-
AMEX Accepts Callisto Pharmaceuticals' Plan of Compliance and Extension to Regain Compliance with Standards
8/29/2007